Tren

Main information

  • Trade name:
  • Tren Capsule
  • Medicine domain:
  • Humans
  • Medicine type:
  • Allopathic drug

Documents

Localization

  • Available in:
  • Tren Capsule
    Malaysia
  • Language:
  • English

Other information

Status

  • Source:
  • NPRA - National Pharmaceutical Regulatory Agency - Bahagian Regulatori Farmasi Negara
  • Authorization number:
  • MAL 1999143
  • Last update:
  • 28-05-2018

Patient Information leaflet

Consumer Medication Information Leaflet (RiMUP)

TREN CAPSULE

Tranexamic Acid (250 mg)

What is in this leaflet

What TREN CAPSULE is used for.

How TREN CAPSULE works.

Before you use TREN CAPSULE.

How to take TREN CAPSULE

While

using

TREN

CAPSULE

Side effects.

Storage

disposal

TREN

CAPSULE

Product description

Manufacturer

Product

Registration Holder

Date of revision

What TREN CAPSULE is used for

TREN CAPSULE is used to treat or prevent

severe bleeding.

How TREN CAPSULE works

TREN

CAPSULE

contains

active

ingredient call tranexamic acid. Tranexamic

acid

antifibrinolytic

agent

which

regulates

balance

between

blood

coagulation and bleeding.

Before you use TREN CAPSULE

When you must not take it

Do not take TREN CAPSULE if you have

allergy

towards

components

TREN

CAPSULE. Avoid taking TREN CAPSULE if

pregnant

breastfeeding.

Patients

with history or risk of thrombosis (eg. stroke,

heart attack, deep vein thrombosis etc.) should

take

TREN

CAPSULE

without

consultation with the doctor.

Before you start to take it

Tell

your

doctor

pharmacist

allergic to any medicines or if you have any

other health related problems (especially renal

diseases and thrombotic diseases).

Taking other medicines

Seek for your doctor or pharmacist advice if

you intended to use TREN CAPSULE together

with

other

medication,

such

oral

contraceptives, medication consists of Factor

IX complex. Besides, you must also inform

them about all the medicines you are taking,

including those without a prescription.

How to take TREN CAPSULE

How much to take

Usual dose is 4 to 6 capsules, two to three

times daily.

When to take it

TREN CAPSULE should be taken upon

instruction given by the doctor or

pharmacist.

How long to take it

TREN CAPSULE should be taken as

your doctor advised you to do so.

If you forgot to take it

If you miss a dose of TREN CAPSULE,

and you are taking it regularly, take it as

soon as possible. If it is approaching

time for the next dose, do not double the

dose to make up for the forgotten dose,

unless

advised

your

health

care

provider. Do not take 2 doses at once.

If you take too much (overdose)

Seek

medical

attention

immediately.

Symptoms

over

dosage

nausea,

vomiting

orthostatic

hypotension (a temporary lowering of

blood

pressure,

usually

related

suddenly standing up).

While you are using TREN

CAPSULE

Things you must do

Follow your doctor’s instruction when

you are taking TREN CAPSULE.

Things you must not do

stop

taking

this

medicine

change

dosing

regimen

without

instruction

from

your

doctor.

give

this

medication

anyone

else,

even if they have the same condition as

you.

Things to be careful of

If you wish to take medication(s) other

than

TREN

CAPSULE,

should

consult

with

doctor

pharmacist.

experience

disturbances

color

vision during course of treatment should

promptly discontinue TREN CAPSULE

and consult your doctor immediately.

Side effects

Common side effects of TREN

CAPSULE are anorexia (lack or loss

appetite for food), hypnosis (half-

consciousness), pruritis (itching),

erythema (abnormal redness of the skin

due to local congestion), skin rash, and

heartburn (burning sensation in the

chest).

Gastrointestinal disturbances (such as nausea,

vomiting, diarrhea) may occur.

You may report any side effects or adverse

drug reactions directly to the National Centre

Adverse

Drug

Reaction

Monitoring

calling Tel: 03-78835550, or visiting the

website portal.bpfk.gov.my

(Consumers

Reporting)

Storage and Disposal

Storage

Store

below

30ºC,

protect

from

light

&

moisture.

Disposal

Dispose when you stop taking the tablets as

instructed by your doctor or pharmacist or the

tablets

have

passed

their

expiry

date.

them what to do with any tablets that are left

over.

Product description

What it looks like

An orange cap and yellow body hard gelatin

capsule,

containing

white

off-white

powder.

Ingredients

Active Ingredient-

Tranexamic acid

Inactive Ingredients-

Lactose

Talc

Aerosil

Magnesium Stearate

MAL no.

MAL 19991436AZ

Manufacturer & Product Registration

Holder

Y.S.P Industries (M) Sdn. Bhd.

Lot 3,5 & 7, Jalan P/7, Section 13,

Kawasan Perindustrian Bandar Baru Bangi,

43000 Kajang, Selangor Darul Ehsan,

Malaysia.

Date of revision :

28 October 2015

Serial Number:

BPFK(R4/1)070715/00178

9-1-2018

Adding Folic Acid to Corn Masa Flour May Prevent Birth Defects

Adding Folic Acid to Corn Masa Flour May Prevent Birth Defects

When consumed by women before and during pregnancy, folic acid, a B vitamin, may help prevent neural tube defects (NTDs).

FDA - U.S. Food and Drug Administration

3-8-2012

Danish Pharmacovigilance Update, 21 June 2012

Danish Pharmacovigilance Update, 21 June 2012

Among the topics covered in this issue of Danish Pharmacovigilance Update are: Decrease in the number of intoxications and suicide attempts using drugs containing acetylsalicylic acid or paracetamol.

Danish Medicines Agency

14-6-2010

Changes in reimbursements for anti-ulcer medicines

Changes in reimbursements for anti-ulcer medicines

The Reimbursement Committee and the Danish Medicines Agency have reviewed medicinal products for the treatment of heartburns, sour eructations and ulcers ('acid-related disorders') in order to assess whether they meet the criteria for public reimbursement.

Danish Medicines Agency

9-4-2010

Consultation responses on the Reimbursement Committee’s recommendation concerning the reimbursement status of medicinal products in ATC group A02 (drugs for acid related disorders)

Consultation responses on the Reimbursement Committee’s recommendation concerning the reimbursement status of medicinal products in ATC group A02 (drugs for acid related disorders)

The Reimbursement Committee’s recommendation concerning the future reimbursement status of medicinal products in ATC group A02 (drugs for acid related disorders) was open for consultation until 15 March 2010.

Danish Medicines Agency

17-12-2009

Consultation on the Reimbursement Committee's recommendation concerning the reimbursement status of medicinal products in ATC group A02 (drugs for acid related disorders)

Consultation on the Reimbursement Committee's recommendation concerning the reimbursement status of medicinal products in ATC group A02 (drugs for acid related disorders)

At the request of the Danish Medicines Agency, the Reimbursement Committee has reassessed the reimbursement status of medicinal products in ATC group A02 (drugs for acid related disorders).

Danish Medicines Agency

4-6-2018

Chenodeoxycholic acid Leadiant (Leadiant GmbH)

Chenodeoxycholic acid Leadiant (Leadiant GmbH)

Chenodeoxycholic acid Leadiant (Active substance: chenodeoxycholic acid) - Centralised - Yearly update - Commission Decision (2018)3627 of Mon, 04 Jun 2018

Europe -DG Health and Food Safety

1-6-2018

Valproate

Valproate

Valproate (Active substance: medicinal products containing substances related to valproate (sodium valproate, valproic acid, valproate semisodium, valpromide, valproate magnesium)) - Community Referrals - Art 31 - Commission Decision (2018)3623 of Fri, 01 Jun 2018 European Medicines Agency (EMA) procedure number: EMEA/H/A-31/1454

Europe -DG Health and Food Safety

29-5-2018

EU/3/14/1400 (Orphan Europe S.A.R.L.)

EU/3/14/1400 (Orphan Europe S.A.R.L.)

EU/3/14/1400 (Active substance: (1S,4R,5R,7S)-3,4-dibenzyl-2-oxo-6,8-dioxa-3-azabyciclo[3.2.1]octane-7-carboxylic acid-L-lysine) - Transfer of orphan designation - Commission Decision (2018)3402 of Tue, 29 May 2018 European Medicines Agency (EMA) procedure number: EMA/OD/185/14/T/01

Europe -DG Health and Food Safety

29-5-2018

EU/3/10/826 (Eurocept International B.V.)

EU/3/10/826 (Eurocept International B.V.)

EU/3/10/826 (Active substance: Para-aminosalicylic acid) - Transfer of orphan designation - Commission Decision (2018)3396 of Tue, 29 May 2018 European Medicines Agency (EMA) procedure number: EMA/OD/072/10/T/02

Europe -DG Health and Food Safety

18-5-2018

EU/3/14/1328 (Roche Registration GmbH)

EU/3/14/1328 (Roche Registration GmbH)

EU/3/14/1328 (Active substance: 4-{[(2R,3S,4R,5S)-4-(4-chloro-2-fluoro-phenyl)-3-(3-chloro-2-fluoro-phenyl)-4-cyano-5-(2,2-dimethyl-propyl)-pyrrolidine-2-carbonyl]-amino}-3-methoxy-benzoic acid) - Transfer of orphan designation - Commission Decision (2018)3149 of Fri, 18 May 2018 European Medicines Agency (EMA) procedure number: EMA/OD/100/14/T/01

Europe -DG Health and Food Safety

18-5-2018

EU/3/13/1220 (IQVIA RDS Ireland Limited)

EU/3/13/1220 (IQVIA RDS Ireland Limited)

EU/3/13/1220 (Active substance: Poly[2-[(4-{[1-carboxy-2-(hexadecylcarbamoyl)ethyl]sulfanyl}-2,3-bis({2-[((2S)-2-(2-{[(2R)-2-carbamoyl-(2-{[(2S)-1-ethoxy-3-(3-hydroxy-4oxo-1,4-dihydropyridin-1-yl)-1-oxopropan-2-yl]carbamoyl}ethyl]sulfanyl}-3-{[(2S)-1-ethoxy-3-(3-hydroxy-4-oxo-1,4-dihydropyridin-1-yl)-1-oxopropan-2-yl]carbamoyl}propanamido)-3-(3-hydroxy-4-oxo-1,4-dihydropyridin-1-yl)propanoyl Ethyl ester) )-methoxy]acetyl}oxy)butyl)sulfanyl]-3-(hexadecylcarbamoyl)propanoic acid]-poly(ethylene glycol)-este...

Europe -DG Health and Food Safety

15-5-2018

Orphacol (Laboratoires CTRS)

Orphacol (Laboratoires CTRS)

Orphacol (Active substance: Cholic acid) - Centralised - Yearly update - Commission Decision (2018)3061 of Tue, 15 May 2018

Europe -DG Health and Food Safety

18-4-2018

EU/3/18/2007 (Dr Philippe Moullier)

EU/3/18/2007 (Dr Philippe Moullier)

EU/3/18/2007 (Active substance: Adeno-associated viral vector serotype 8 containing the human acid alpha-glucosidase gene) - Orphan designation - Commission Decision (2018)2403 of Wed, 18 Apr 2018 European Medicines Agency (EMA) procedure number: EMA/OD/255/17

Europe -DG Health and Food Safety

23-3-2018

EU/3/18/1991 (TurnKey PharmaConsulting Ireland Limited)

EU/3/18/1991 (TurnKey PharmaConsulting Ireland Limited)

EU/3/18/1991 (Active substance: Docosahexaenoic acid ethyl ester) - Orphan designation - Commission Decision (2018)1880 of Fri, 23 Mar 2018 European Medicines Agency (EMA) procedure number: EMA/OD/235/17

Europe -DG Health and Food Safety

23-3-2018

EU/3/18/2000 (Amicus Therapeutics UK Ltd)

EU/3/18/2000 (Amicus Therapeutics UK Ltd)

EU/3/18/2000 (Active substance: Recombinant human acid alpha-glucosidase) - Orphan designation - Commission Decision (2018)1877 of Fri, 23 Mar 2018 European Medicines Agency (EMA) procedure number: EMA/OD/230/17

Europe -DG Health and Food Safety

21-3-2018

EU/3/17/1861 (Roivant Sciences Ireland Limited)

EU/3/17/1861 (Roivant Sciences Ireland Limited)

EU/3/17/1861 (Active substance: (S)-8-{2-amino-6-[1-(5-chloro-biphenyl-2-yl)-(R)-2,2,2-trifluoro-ethoxy]-pyrimidin-4-yl}-2,8-diaza-spiro[4.5]decane-3-carboxylic acid ethyl ester) - Transfer of orphan designation - Commission Decision (2018)1826 of Wed, 21 Mar 2018 European Medicines Agency (EMA) procedure number: EMA/OD/299/16/T/01

Europe -DG Health and Food Safety

21-3-2018

EU/3/14/1363 (IQVIA RDS Ireland Limited)

EU/3/14/1363 (IQVIA RDS Ireland Limited)

EU/3/14/1363 (Active substance: 4-[[(1S,4S)-5-[[4-[4-(oxazol-2-yl)phenoxy]phenyl]methyl]-2,5-diazabicyclo[2.2.1]hept-2-yl]methyl]benzoic acid) - Transfer of orphan designation - Commission Decision (2018)1818 of Wed, 21 Mar 2018 European Medicines Agency (EMA) procedure number: EMA/OD/131/14/T/01

Europe -DG Health and Food Safety

8-3-2018

Mycophenolate mofetil, mycophenolic acid

Mycophenolate mofetil, mycophenolic acid

Mycophenolate mofetil, mycophenolic acid (Active substance: mycophenolate mofetil or mycophenolic acid) - Centralised - Art 28 - (PSUR - Commission Decision (2018)1540 of Thu, 08 Mar 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/PSUSA/10550/201705

Europe -DG Health and Food Safety

5-2-2018

Oxybee (Dany Bienenwohl GmbH)

Oxybee (Dany Bienenwohl GmbH)

Oxybee (Active substance: oxalic acid dihydrate) - New authorisation - Commission Decision (2018)684 of Mon, 05 Feb 2018 European Medicines Agency (EMA) procedure number: EMEA/V/C/4296

Europe -DG Health and Food Safety

24-11-2017

Gadolinium

Gadolinium

Gadolinium (Active substance: gadodiamide, gadopentetic acid, gadobenic acid, gadoxetic acid, gadoteridol, gadobutrol and gadoteric acid) - Community Referrals - Art 31 - Commission Decision (2017)7941 of Fri, 24 Nov 2017 European Medicines Agency (EMA) procedure number: EMEA/H/A-31/1437

Europe -DG Health and Food Safety